Mortality Risk of Darbepoetin Alfa Versus Epoetin Alfa in Patients with CKD: Systematic Review and Meta-analysis

Overview

Journal Am J Kidney Dis

Specialty Nephrology

Date 2015 Feb 1

PMID 25636816

Citations 15

Authors

Emilee R Wilhelm-Leen

Wolfgang C Winkelmayer

Affiliations

Soon will be listed here.

Abstract

Background: Epoetin alfa (EPO) and darbepoetin alfa (DPO) are erythropoiesis-stimulating agents that are widely and interchangeably used for the treatment of anemia in patients with advanced chronic kidney disease and end-stage renal disease. No study has specifically compared the risks of hard study outcomes between EPO and DPO, including mortality.

Study Design: Systematic review of the literature and meta-analysis.

Setting & Population: Patients enrolled in randomized trials comparing EPO versus DPO for the treatment of anemia in adults with chronic kidney disease, including those requiring dialysis.

Selection Criteria For Studies: We conducted a systematic search of the literature (PubMed, CENTRAL, SCOPUS, and EMBASE, all years) and industry resources, using predefined search terms and data abstraction tools. We then summarized key characteristics and findings of these trials and performed a random-effects meta-analysis of trials with at least 3 months' duration to identify the summary OR of mortality between patients randomly assigned to DPO versus EPO.

Intervention: DPO versus EPO.

Outcome: All-cause mortality.

Results: We identified 9 trials that met the stated inclusion criteria. Overall, 2,024 patients were included in the meta-analysis, of whom 126 died during follow-up, which ranged from 20 to 52 weeks. We found no significant difference in mortality between patients randomly assigned to DPO versus EPO (OR, 1.33; 95% CI, 0.88-2.01). No treatment heterogeneity across studies was detected (Q statistic=4.60; P=0.8).

Limitations: Generalizability to nontrial populations is uncertain.

Conclusions: Few trials directly comparing DPO and EPO have been conducted and follow-up was limited. In aggregate, no effect of specific erythropoiesis-stimulating agent on mortality was identified, but the confidence limits were wide and remained compatible with considerable harm from DPO. Absent adequately powered randomized trials, observational postmarketing comparative effectiveness studies comparing these erythropoiesis-stimulating agents are required to better characterize the long-term safety profiles of these agents.

Citing Articles

Risk factors and current state of therapy for anemia after kidney transplantation.

Tang Y, Guo J, Zhou J, Wan Z, Li J, Qiu T Front Med (Lausanne). 2024; 10:1170100.

PMID: 38264045 PMC: 10804853. DOI: 10.3389/fmed.2023.1170100.

Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).

Csiky B, Schomig M, Esposito C, Barratt J, Reusch M, Valluri U Adv Ther. 2021; 38(10):5361-5380.

PMID: 34537926 PMC: 8478768. DOI: 10.1007/s12325-021-01904-6.

Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study.

Xu Y, Evans M, Barany P, James G, Sjolander A, Carrero J Clin Kidney J. 2021; 14(7):1780-1788.

PMID: 34221385 PMC: 8243267. DOI: 10.1093/ckj/sfaa213.

Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality.

Karaboyas A, Port F, Massy Z, Locatelli F, Cases A, Nitta K Kidney Int Rep. 2021; 6(1):214-218.

PMID: 33426400 PMC: 7783558. DOI: 10.1016/j.ekir.2020.10.003.

Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach.

Moradi Z, Maali A, Shad J, Farasat A, Kouchaki R, Moghadami M Indian J Hematol Blood Transfus. 2020; 36(1):26-36.

PMID: 32174689 PMC: 7042474. DOI: 10.1007/s12288-019-01170-1.

References

Portoles J, de Francisco A, Gorriz J, Martinez-Castelao A, Lopez-Gomez J, Arias M . Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. Kidney Int Suppl. 2008; (111):S82-7. DOI: 10.1038/ki.2008.524. View

Bennett C, Jacob S, Hymes J, Usvyat L, Maddux F . Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. 2014; 370(21):2055-6. PMC: 4200528. DOI: 10.1056/NEJMc1400883. View

Vanrenterghem Y, Barany P, Mann J, Kerr P, Wilson J, Baker N . Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002; 62(6):2167-75. DOI: 10.1046/j.1523-1755.2002.00657.x. View

Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T . Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014; 86(4):845-54. DOI: 10.1038/ki.2014.114. View

Lappin T, Maxwell A, Johnston P . EPO's alter ego: erythropoietin has multiple actions. Stem Cells. 2002; 20(6):485-92. DOI: 10.1634/stemcells.20-6-485. View

Bernieh B, Abouchacra S, Boobes Y, Al Hakim M, Nagelkerke N, Chaaban A . Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome. Int Urol Nephrol. 2014; 46(2):453-9. PMC: 3932161. DOI: 10.1007/s11255-013-0640-7. View

Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M . Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85(3):221-8. DOI: 10.1161/01.res.85.3.221. View

Weiss M . New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist. 2003; 8 Suppl 3:18-29. DOI: 10.1634/theoncologist.8-suppl_3-18. View

Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M . Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004; 305(5681):239-42. DOI: 10.1126/science.1098313. View

10.

Li W, Chu T, Huang J, Wu M, Wu K . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. J Formos Med Assoc. 2008; 107(11):843-50. DOI: 10.1016/S0929-6646(08)60200-4. View

11.

Bahlmann F, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm S . Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003; 64(5):1648-52. DOI: 10.1046/j.1523-1755.2003.00279.x. View

12.

Macdougall I, Gray S, Elston O, Breen C, Jenkins B, Browne J . Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999; 10(11):2392-5. DOI: 10.1681/ASN.V10112392. View

13.

Egrie J, Browne J . Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001; 16 Suppl 3:3-13. View

14.

Dzau V, Gnecchi M, Pachori A, Morello F, Melo L . Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension. 2005; 46(1):7-18. DOI: 10.1161/01.HYP.0000168923.92885.f7. View

15.

Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I . A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2005; 102(6):2046-51. PMC: 548534. DOI: 10.1073/pnas.0409329102. View

16.

Maiese K, Li F, Chong Z . New avenues of exploration for erythropoietin. JAMA. 2005; 293(1):90-5. PMC: 2254180. DOI: 10.1001/jama.293.1.90. View

17.

Fliser D, Haller H . Erythropoietin and treatment of non-anemic conditions--cardiovascular protection. Semin Hematol. 2007; 44(3):212-7. DOI: 10.1053/j.seminhematol.2007.04.008. View

18.

Bahlmann F, Groot K, Spandau J, Landry A, Hertel B, Duckert T . Erythropoietin regulates endothelial progenitor cells. Blood. 2003; 103(3):921-6. DOI: 10.1182/blood-2003-04-1284. View

19.

Singh A . Does TREAT give the boot to ESAs in the treatment of CKD anemia?. J Am Soc Nephrol. 2009; 21(1):2-6. DOI: 10.1681/ASN.2009111127. View

20.

Yang W, Israni R, Brunelli S, Joffe M, Fishbane S, Feldman H . Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007; 18(12):3164-70. DOI: 10.1681/ASN.2007010058. View